(4S,4aS,5aR,12aS)-4-(dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide | 61618-26-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 四环素类
• 英文名称: (4S,4aS,5aR,12aS)-4-(dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
• 英文别名: 7-fluorosancycline
• CAS: 61618-26-6
• 化学式: C₂₁H₂₁FN₂O₇
• 分子量: 432.405
• InChiKey: CBKMYVQVIYQZDH-UVPAEMEASA-N

物化性质

• 沸点：
  767.2±60.0 °C(Predicted)
• 密度：
  1.65±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.26
• 重原子数：
  31.0
• 可旋转键数：
  2.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  161.39
• 氢给体数：
  5.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  (4S,4aS,5aR,12aS)-4-(dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide 在 硫酸 、 palladium 10% on activated carbon 、 氢气 、 硝酸 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 3.0h， 生成 (4S,4aS,5aR,12aS)-9-[2-(tert-butylamino)acetamido]-4-(dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide dihydrochloride
  参考文献：
  名称：

  Fluorocyclines. 1. 7-Fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: A Potent, Broad Spectrum Antibacterial Agent

  摘要：

  This and the accompanying report (DOI: 10.1021/jm201467r) describe the design, synthesis, and evaluation of a new generation of tetracycline antibacterial agents, 7-fluoro-9-substituted-6-demethyl-6-deoxytetracyclines ("fluorocyclines"), accessible through a recently developed total synthesis approach. These fluorocyclines possess potent antibacterial activities against multidrug resistant (MDR) Gram-positive and Gram-negative pathogens. One of the fluorocyclines, 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline (17j, also known as TP-434, 50th Interscience Conference on Antimicrobial Agents and Chemotherapy Conference, Boston, MA, September 12-15, 2010, poster F1-2157), is currently undergoing phase 2 clinical trials in patients with complicated intra-abdominal infections (cIAI).

  DOI：

  10.1021/jm201465w
• 作为产物：
  描述：

  7-fluorosancycline hexafluorophosphoric acid 在 sodium hydroxide 作用下， 以 水 为溶剂， 以11.3 g的产率得到(4S,4aS,5aR,12aS)-4-(dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
  参考文献：
  名称：

  [EN] SEMI-SYNTHESIS PROCEDURES
  [FR] PROCÉDURES DE SEMI-SYNTHÈSE

  摘要：

  本文提供了改进的过程，用于将C7-氨基取代四环素转化为C7-氟取代四环素，以及由这些过程产生或使用的中间体。在一种实施方式中，提供了一种热氟化方法，其中治疗悬浮液包括非极性有机溶剂和C7-重氮基取代的四环素六氟磷酸盐、六氟砷酸盐或六氟硅酸盐，或其盐、溶剂或其组合物，以提供C7-氟取代四环素，或其盐、溶剂或其组合物。在另一种实施方式中，提供了一种光解氟化方法，其中治疗溶液包括离子液体和C-7重氮基取代的四环素四氟硼酸盐、六氟磷酸盐、六氟砷酸盐或六氟硅酸盐，或其盐、溶剂或其组合物，经辐射后可提供C7-氟取代四环素，或其盐、溶剂或其组合物。

  公开号：

  WO2016065290A1

文献信息

• [EN] C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS<br/>[FR] COMPOSÉS DE TÉTRACYCLINE C7-FLUOROSUBSTITUÉE
  申请人：TETRAPHASE PHARMACEUTICALS INC

  公开号：WO2010017470A1

  公开（公告）日：2010-02-11

  The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.

  本发明涉及一种由结构式（A）表示的化合物，或其药学上可接受的盐。结构式（A）的变量在此处定义。还描述了包括结构式（A）化合物的药物组合物及其治疗用途。
• C7-fluoro substituted tetracycline compounds
  申请人：Tetraphase Pharmaceuticals, Inc.

  公开号：EP2682387A2

  公开（公告）日：2014-01-08

  The present invention is directed to a compound falling under Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.

  本发明涉及一种属于结构式（A）的化合物： 或其药学上可接受的盐。结构式（A）的变量在此定义。还描述了一种包含结构式（A）化合物的药物组合物及其治疗用途。
• Semi-synthesis procedures
  申请人：Tetraphase Pharmaceuticals, Inc.

  公开号：US10618879B2

  公开（公告）日：2020-04-14

  Provided herein are improved processes for converting C7-amino-substituted tetracyclines to C7-fluoro-substituted tetracyclines, as well as intermediates produced by or used in these processes. In one embodiment, a thermal fluorination method is provided in which a suspension comprising a non-polar organic solvent and a C7-diazo-substituted tetracycline hexafluorophosphate, hexafluoroarsenate or hexafluorosilicate salt, or a salt, solvate or combination thereof, is heated to provide a C7-fluoro-substituted tetracycline, or salt, solvate or combination thereof. In another embodiment, a photolytic fluorination is provided in which a solution comprising an ionic liquid and a C7-diazo-substituted tetracycline tetrafluoroborate, hexafluorophosphate, hexafluoroarsenate or hexafluorosilicate salt, or a salt, solvate or combination thereof, is irradiated to provide a C7-fluoro-substituted tetracycline, or salt, solvate or combination thereof.

  本文提供了将 C7-氨基取代的四环素转化为 C7-氟取代的四环素的改进工艺，以及由 这些工艺生产或在这些工艺中使用的中间体。在一个实施方案中，提供了一种热氟化方法，将包含非极性有机溶剂和 C7-重氮取代的四环素六氟磷酸盐、六氟砷酸盐或六氟硅酸盐或其盐、溶液或其组合的悬浮液加热，以提供 C7-氟取代的四环素或其盐、溶液或其组合。在另一个实施方案中，提供了一种光解氟化方法，其中包含离子液体和 C7-重氮取代的四环素四氟硼酸盐、六氟磷酸酯、六氟砷酸盐或六氟硅酸盐或其盐、溶液或其组合的溶液经过辐照以提供 C7-氟取代的四环素或其盐、溶液或其组合。
• Fluorocyclines. 2. Optimization of the C-9 Side-Chain for Antibacterial Activity and Oral Efficacy
  作者：Roger B. Clark、Diana K. Hunt、Minsheng He、Catherine Achorn、Chi-Li Chen、Yonghong Deng、Corey Fyfe、Trudy H. Grossman、Philip C. Hogan、William J. O’Brien、Louis Plamondon、Magnus Rönn、Joyce A. Sutcliffe、Zhijian Zhu、Xiao-Yi Xiao

  DOI：10.1021/jm201467r

  日期：2012.1.26

  Utilizing a fully synthetic route to tetracycline analogues, the C-9 side-chain of the fluorocyclines was optimized for both antibacterial activity and oral efficacy. Compounds were identified that overcome both efflux (tet(K), tet(A)) and ribosomal protection (tet(M)) tetracycline-resistance mechanisms and are active against Gram-positive and Gram-negative organisms. A murine systemic infection model was used as an oral efficacy screen to rapidly identify compounds with oral bioavailability. Two compounds were identified that exhibit both oral bioavailability in rat and clinically relevant bacterial susceptibility profiles against major respiratory pathogens. One compound demonstrated oral efficacy in rodent lung infection models that was comparable to marketed antibacterial agents,
• J. Med. Chem. 2012, 55, 597-605
  作者：

  DOI：——

  日期：——